Ferumoxytol is approved in the United States (U.S.) for treatment of iron deficiency anemia in chronic kidney disease. However, its superparamagnetic properties can be leveraged for off-label use in MRI. In 2015, the U.S. Food and Drug Administration (FDA) issued a “black-box” warning regarding risk of rare but serious hypersensitivity reactions based on post-marketing surveillance therapeutic use data. Preliminary experience from the FeraSafe Multi-Center RegistryTM suggests a low incidence of adverse events with the off-label diagnostic use of ferumoxytol. To date, these preliminary results suggest that with appropriate clinical use and monitoring, there is an acceptable benefit /risk profile.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords